Non-HLA angiotensin-type-1 receptor autoantibodies mediate the long-term loss of grafted neurons in Parkinson's disease models.

Ana I Rodríguez-PérezPablo Garrido-GilMaria García-GarroteAna MuñozJuan A PargaJose Luis Labandeira-GarciaJannette Rodríguez-Pallares

Published in: Stem cell research & therapy (2024)

The results suggest the use of ARBs such as candesartan in PD patients, particularly before and after dopaminergic grafts, and the need to monitor AT1-AA levels in PD patients, particularly in those candidates for dopaminergic grafting.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
systemic lupus erythematosus
spinal cord
angiotensin ii
patient reported outcomes
angiotensin converting enzyme